Literature DB >> 3481244

In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.

R J Fass1, V L Helsel.   

Abstract

MICs of pefloxacin and nine antistaphylococcal drugs were determined for 200 isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saprophyticus. All the strains were susceptible to pefloxacin, vancomycin, and rifampin. Oxacillin-resistant strains were uniformly resistant to cephalothin and were more likely to be resistant to gentamicin, erythromycin, clindamycin, doxycycline, and trimethoprim-sulfamethoxazole than were oxacillin-susceptible strains. Time-kill studies with 23 strains of S. aureus, S. epidermidis, and S. haemolyticus indicated that the relative order of bactericidal activities was gentamicin greater than or equal to pefloxacin greater than oxacillin greater than vancomycin greater than rifampin. Pefloxacin combined with oxacillin or vancomycin killed staphylococci more rapidly than oxacillin or vancomycin alone but less rapidly than pefloxacin alone. Gentamicin combined with oxacillin, vancomycin, or pefloxacin resulted in the most rapid killing of gentamicin-susceptible strains. Rifampin combined with oxacillin, vancomycin, or pefloxacin reduced the bactericidal activities of those drugs, but rifampin resistance was not observed as it was with rifampin alone. Pefloxacin is a potentially useful antistaphylococcal agent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481244      PMCID: PMC174970          DOI: 10.1128/AAC.31.10.1457

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.

Authors:  G L Mandell; T K Vest
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

Review 2.  Staphylococcus epidermidis infections.

Authors:  F D Lowy; S M Hammer
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

3.  Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.

Authors:  O Korzeniowski; M A Sande
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

4.  Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.

Authors:  C Watanakunakorn; J C Tisone
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

5.  Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants.

Authors:  M H Miller; M A Wexler; N H Steigbigel
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

6.  In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.

Authors:  R J Fass; V L Helsel
Journal:  Diagn Microbiol Infect Dis       Date:  1987-04       Impact factor: 2.803

7.  Elimination of indigenous measles from the United States.

Authors:  A R Hinman; C D Kirby; D L Eddins; W A Orenstein; R H Bernier; P M Turner; K J Bart
Journal:  Rev Infect Dis       Date:  1983 May-Jun

8.  Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus.

Authors:  D E Craven; N R Kollisch; C R Hsieh; M G Connolly; W R McCabe
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

9.  Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis.

Authors:  M A Sande; K B Courtney
Journal:  J Lab Clin Med       Date:  1976-07

10.  Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy.

Authors:  A W Karchmer; G L Archer; W E Dismukes
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

View more
  12 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Penetration of pefloxacin into maxillary sinus cavity and nasal secretions.

Authors:  G Petrikkos; P Goumas; E Moschovakis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 3.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  D Bahl; D A Miller; I Leviton; P Gialanella; M J Wolin; W Liu; R Perkins; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.

Authors:  R Dworkin; G Modin; S Kunz; R Rich; O Zak; M Sande
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 7.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.

Authors:  O Petitjean; B Pangon; N Brion; M Tod; C Chaplain; V Le Gros; K Louchahi; P Allouch
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 10.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.